# RHHBY PDUFA Calendar: FDA Decision Dates & Catalyst Timeline

Canonical URL: https://biopharmsignal.com/pdufa-calendar/RHHBY
Company: Roche Holdings AG

BioPharmSignal tracks active PDUFA and FDA decision milestones associated with RHHBY.

## RHHBY PDUFA Milestones

- 2026-10-09 — PDUFA — FDA decision expected. FDA assigned an October 9, 2026 PDUFA goal date to the supplemental BLA for TECENTRIQ and TECENTRIQ HYBREZA in combination with chemot...
  Company: Roche Holdings AG
  Source: https://www.roche.com/media/releases/med-cor-2026-06-11
  Event detail: https://biopharmsignal.com/pdufa-calendar/RHHBY/tecentriq-adjuvant-stage-iii-dmmr-msi-h-colon-cancer.md
  Month page: https://biopharmsignal.com/pdufa-calendar/2026/october (October 2026)
- 2026-10-15 — PDUFA — FDA decision expected. FDA assigned an October 15, 2026 PDUFA goal date to the ENSPRYNG supplemental BLA for thyroid eye disease.
  Company: Roche Holdings AG
  Source: https://www.roche.com/investors/updates/inv-update-2026-06-30
  Event detail: https://biopharmsignal.com/pdufa-calendar/RHHBY/enspryng-thyroid-eye-disease.md
  Month page: https://biopharmsignal.com/pdufa-calendar/2026/october (October 2026)

## Related Pages

- Company page: https://biopharmsignal.com/company/RHHBY
- Interactive PDUFA Calendar: https://biopharmsignal.com/pdufa-calendar

## FAQ

### What does the RHHBY PDUFA calendar show?

It shows active PDUFA and FDA decision milestones associated with RHHBY, including decision dates, application stage, and summary details when available.
### Where can I find more context for RHHBY?

Use the BioPharmSignal company page for RHHBY to read related news, stock data, sector context, and company-specific updates.
### Are these dates investment advice?

No. PDUFA dates are research inputs, not investment recommendations. Always review primary sources and understand the clinical and regulatory context.